Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial.
Pharmacotherapy 2001;
21:263-74. [PMID:
11256381 DOI:
10.1592/phco.21.3.263.34198]
[Citation(s) in RCA: 99] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
STUDY OBJECTIVE
To compare hospital length of stay (LOS), weekly discharges, and days of antibiotic treatment with linezolid (intravenous with oral follow-up) and vancomycin (intravenous only).
DESIGN
Multinational, randomized, phase III trial.
SETTINGS
Hospitals in North America, Latin America, and Europe.
PATIENTS
Four hundred sixty hospitalized patients with infections of known or suspected methicillin-resistant Staphylococcus species.
INTERVENTION
Administration of linezolid or vancomycin.
MEASUREMENTS AND MAIN RESULTS
For linezolid recipients, median LOS was 5 and 8 days shorter (p=0.05 and 0.003) in the complicated skin and soft tissue infection intent-to-treat (230 patients) and clinically evaluable (144) samples, and slightly but not significantly shorter in the overall intent-to-treat (460) and clinically evaluable (254) samples. In all samples, linezolid recipients had more discharges in the first week of treatment and fewer days of intravenous therapy than vancomycin recipients.
CONCLUSION
Our results support linezolid's ability to reduce medical resource use.
Collapse